GLP-1 Medicines: What They Do and Who They Help

GLP-1 is a hormone released by the gut after eating. Medicines that activate its receptor increase insulin release when glucose is high, reduce glucagon release, and influence appetite. They also delay stomach emptying. Together, these effects can make smaller meals satisfying and help reduce energy intake.

Tirzepatide acts on both the GLP-1 and GIP receptors. It is often grouped with GLP-1 medicines in weight-treatment discussions, although its action involves two hormone pathways. These medicines require a prescription and monitoring; the effects continue to depend on treatment, tolerability, and nutrition.

Diabetes brands such as Ozempic and Mounjaro have their own labels. Sharing an ingredient with a weight-treatment brand does not make the products interchangeable. Ask for the exact brand and formulation whenever a service advertises a general 'GLP-1 program.'

For adult weight treatment, clinicians commonly consider medication at a BMI of 30 or above, or 27 or above with a weight-related condition such as high blood pressure or type 2 diabetes. Those thresholds help identify candidates. The decision also considers previous treatment, other medicines, pregnancy plans, and whether ongoing care is practical.

The medicines in the table are contraindicated with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Tell the prescriber about pancreatitis, gallbladder disease, severe stomach-emptying problems, kidney problems, and diabetes-related eye disease. Pregnancy and breastfeeding require specific discussion.

Treatment usually begins at a low dose and increases over time to reduce digestive effects. Nausea, diarrhea, constipation, vomiting, and abdominal discomfort are common. If eating or drinking becomes difficult, the prescribing team should review symptoms before the next increase. Increasing faster can make adverse effects worse.

Severe or persistent abdominal pain, repeated vomiting, dehydration, or a serious allergic reaction needs prompt medical attention. People taking insulin or a sulfonylurea may need changes to those medicines to reduce low-blood-sugar risk. Tell an anesthesia team about GLP-1 treatment before a procedure because delayed stomach emptying can affect care.

• Agree how weight, health conditions, adverse effects, and nutrition will be reviewed.
• Check the ongoing prescription price and insurance requirements separately from service fees.
• Get instructions for the actual pen, vial, or tablet supplied, including missed doses and storage.
• Discuss what happens if treatment becomes unaffordable or needs to stop.

FDA-approved products have been reviewed for safety, effectiveness, and quality. Compounded products have not undergone that approval process. FDA advises using them only when a medical need cannot be met by an approved drug, and warns about dosing errors, fraudulent products, and semaglutide salt forms. Verify the dispensing pharmacy and the exact product before paying.